Evocalcet - Mitsubishi Tanabe Pharma Corporation

Drug Profile

Evocalcet - Mitsubishi Tanabe Pharma Corporation

Alternative Names: Evocalcet; KHK 4580; KHK-7580; MT-4580; ORKEDIA

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Kyowa Hakko Kirin
  • Class Antithyroids; Naphthalenes; Pyrrolidines; Small molecules
  • Mechanism of Action Calcium-sensing receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Secondary hyperparathyroidism
  • Phase III Primary hyperparathyroidism

Most Recent Events

  • 23 Mar 2018 Registered for Secondary hyperparathyroidism in Japan (PO)
  • 23 Mar 2018 Kyowa Hakko Kirin receives MAA from Japan's Ministry of Health, Labor and Welfare (MHLW) for Secondary hyperparathyroidsim in Japan
  • 14 Aug 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top